Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from the patient. The therapy is injected into patients, spurring T-cells to attack the remaining cancer cells after tumor-removal surgery. The vaccine, DCVax-Brain, is being developed by Bothell, WA-based Northwest Biotherapeutics.
"I've never seen a clinical trial that's had this promise," said Dr. Michael Gruber, medical director of the Brain Tumor Center of New Jersey.
- read the article from the Monterey Herald